GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses

References

• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17:6958-62; PMID:21900389; http://dx.doi.org/10.1158/1078-0432.CCR-11-1595
   PubMed Web of Science ®Google Scholar
• Nightingale SL. From the Food and Drug Administration. JAMA 1991; 265:2315; PMID:21900389; http://dx.doi.org/10.1001/jama.1991.03460180021009
   PubMedGoogle Scholar
• Fidler IJ, Kleinerman ES. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 1984; 2:937-43; PMID:6379124
   PubMed Web of Science ®Google Scholar
• Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S, Conlon PJ. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232:506-8; PMID:3083507; http://dx.doi.org/10.1126/science.3083507
   PubMed Web of Science ®Google Scholar
• Thomassen MJ, Barna BP, Rankin D, Wiedemann HP, Ahmad M. Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages. Cancer Res 1989; 49:4086-9; PMID:2545332
   PubMed Web of Science ®Google Scholar
• Chachoua A, Oratz R, Hoogmoed R, Caron D, Peace D, Liebes L, Blum RH, Vilcek J. Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol 1994; 15:217-24; PMID:8032545; http://dx.doi.org/10.1097/00002371-199404000-00008
   PubMed Web of Science ®Google Scholar
• Demir G, Klein HO, Tuzuner N. Low dose daily rhGM-CSF application activates monocytes and dendritic cells in vivo. Leukemia Res 2003; 27:1105-8; PMID:12921948; http://dx.doi.org/10.1016/S0145-2126(03)00097-3
   PubMed Web of Science ®Google Scholar
• Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997; 88:801-10; PMID:9118223; http://dx.doi.org/10.1016/S0092-8674(00)81926-1
   PubMed Web of Science ®Google Scholar
• Young JW, Szabolcs P, Moore MA. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor α. J Exp Med 1995; 182:1111-9; PMID:7561684; http://dx.doi.org/10.1084/jem.182.4.1111
   PubMed Web of Science ®Google Scholar
• Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol 1995; 154:5851-61; PMID:7538534
   PubMed Web of Science ®Google Scholar
• Szabolcs P, Avigan D, Gezelter S, Ciocon DH, Moore MA, Steinman RM, Young JW. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 1996; 87:4520-30; PMID:8639819; http://dx.doi.org.ucsf.idm.oclc.org/
   PubMed Web of Science ®Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000; 18:1614-21; PMID:10764421
   PubMed Web of Science ®Google Scholar
• Grotz TE, Kottschade L, Pavey ES, Markovic SN, Jakub JW. Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study. Am J Clin Oncol 2014; 37:467-72; PMID:23428946; http://dx.doi.org/10.1097/COC.0b013e31827def82
   PubMed Web of Science ®Google Scholar
• Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH et al. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol 2015; 33(34):4066-76; PMID:26351350; http://dx.doi.org/10.1200/JCO.2015.62.0500
   PubMed Web of Science ®Google Scholar
• Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69:609-15; PMID:19147575; http://dx.doi.org/10.1158/0008-5472.CAN-08-3529
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014; 312:1744-53; PMID:25369488; http://dx.doi.org/10.1001/jama.2014.13943
   PubMed Web of Science ®Google Scholar
• AJCC Cancer Staging Manual. New York: Springer, 2010
   Google Scholar
• Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-34; PMID:11504744
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1:126-34; PMID:6668496
   PubMed Web of Science ®Google Scholar
• Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, Garbe C. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79:2345-53; PMID:9191522; http://dx.doi.org/10.1002/(SICI)1097-0142(19970615)79:12<2345::AID-CNCR8>3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000; 18:3782-93; PMID:11078491
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P et al. Bcl−2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24:4738-45; PMID:16966688; http://dx.doi.org/10.1200/JCO.2006.06.0483
   PubMed Web of Science ®Google Scholar
• Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010; 116:155-63; PMID:19877111; http://dx.doi.org/10.1002/cncr.24720
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009; 32:203-5; PMID:19238020; http://dx.doi.org/10.1097/CJI.0b013e318193a206
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372-7; PMID:12826605; http://dx.doi.org/10.1073/pnas.1533209100
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7; PMID:22614989; http://dx.doi.org/10.1200/JCO.2012.41.6750
   PubMed Web of Science ®Google Scholar
• Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013; 24:1697-703; PMID:23439861; http://dx.doi.org/10.1093/annonc/mdt027
   PubMed Web of Science ®Google Scholar
• Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116:1767-75; PMID:20143434; http://dx.doi.org/10.1002/cncr.24951
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PloS one 2014; 9:e87705; PMID:24498358; http://dx.doi.org/10.1371/journal.pone.0087705
   PubMed Web of Science ®Google Scholar
• Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014; 63:675-83; PMID:24695951; http://dx.doi.org/10.1007/s00262-014-1545-8
   PubMed Web of Science ®Google Scholar
• Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney S, Harzstark A, Lin A, Ryan C, Small EJ, Fong L. Pre-existing levels of CD4 T cells expressing PD-1 are related to overall survival in prostate cancer patients treated with ipilimumab. Cancer Immunol Res 2015; 3(9):1008-16; PMID:25968455; http://dx.doi.org/10.1158/2326-6066.CIR-14-0227
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009:15: 1742; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
   Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statistical Assoc 1958; 53:457-81; http://dx.doi.org/10.1080/01621459.1958.10501452
   Web of Science ®Google Scholar